About US
Contact us
>>Back
China Biopharma Congress 2009
- Publisher：
- Publication：2009/11/27
Shanghai International Convention Center, Shanghai , China.
Organisers: Opplandcorp
Email: biopharma@opplandcorp.com
Time for BIG Pharmas to readjust your view of China and Asia.
The financial crisis is reshaping global landscape of pharmaceutical industry. Intead of in-house R&D, big pharmas are more relying on outsourcing and partnership to attain promising pipelines and enhance R&D productivity, however, how to tackle concerns of outsourcing cost management, regulatory compliance and data consistency brought?
China is a leading offshoring destination for biomanufacturing and R&D activity due to its relatively low HR and clinical costs. However, cost is no longer the primary driver. Big pharmas have to balance cost with risk & market opportunity. Is it time for "In China, For China"?
China is more than a outsourcing base for early-stage biotech firms
Deterioration of institutional funding situation in US en EU for early-stage biotech firms is forcing them to look further afield for financing and partners in China and other emerging countries. How to screen out qualified local partners? Any incentives available in China in terms of tax and funding support? Where is the best location? Beijing, Tianjin or Shanghai?
CRO/CMOs surviving strategy
Big pharmas are aggressively looking for ways to cut development expenditures before demonstrating proof-of-concept. Biotechs are being forced to shelve less developed candidates to conserve funds. What's worse, Big pharmas seems are shifting to more integrated outsourcing models under which all activities are consolidated with a single CRO, instead of several. This changing environment is hiting hard CRO/CMOs that focus on early development. Who will be shaken out? Who survive and how?
Instead of fee-for-service model, CRO/CMOs maybe have to shift to risk-sharing models to cater to sponsors, but how? How much risk CRO/CMOs have to take up amid the partnership?
Potential biotech targets/deals for VCs and investors in China
Although lost in China's complex regulations and frightened of IPR issues, VCs based in China and overseas are still eager to pursue potential biotech targets for highly-expected ROI. However, issues including any sources available for potential pipelines screening, how to commercialize your portfolio in China etc pose great challenges to the investors. What's more, how to exit and leave with money in pocket? Is China's upcoming second board stock market a good option?
China BioPharma Congress 2009, the grand finale of China's biopharma industry annually, is designed to gather together 400 executive-level professionals from China and overseas, bring conclusive views on 2009 biopharma industry and foresights on 2010.
The financial crisis is reshaping global landscape of pharmaceutical industry. Intead of in-house R&D, big pharmas are more relying on outsourcing and partnership to attain promising pipelines and enhance R&D productivity, however, how to tackle concerns of outsourcing cost management, regulatory compliance and data consistency brought?
China is a leading offshoring destination for biomanufacturing and R&D activity due to its relatively low HR and clinical costs. However, cost is no longer the primary driver. Big pharmas have to balance cost with risk & market opportunity. Is it time for "In China, For China"?
China is more than a outsourcing base for early-stage biotech firms
Deterioration of institutional funding situation in US en EU for early-stage biotech firms is forcing them to look further afield for financing and partners in China and other emerging countries. How to screen out qualified local partners? Any incentives available in China in terms of tax and funding support? Where is the best location? Beijing, Tianjin or Shanghai?
CRO/CMOs surviving strategy
Big pharmas are aggressively looking for ways to cut development expenditures before demonstrating proof-of-concept. Biotechs are being forced to shelve less developed candidates to conserve funds. What's worse, Big pharmas seems are shifting to more integrated outsourcing models under which all activities are consolidated with a single CRO, instead of several. This changing environment is hiting hard CRO/CMOs that focus on early development. Who will be shaken out? Who survive and how?
Instead of fee-for-service model, CRO/CMOs maybe have to shift to risk-sharing models to cater to sponsors, but how? How much risk CRO/CMOs have to take up amid the partnership?
Potential biotech targets/deals for VCs and investors in China
Although lost in China's complex regulations and frightened of IPR issues, VCs based in China and overseas are still eager to pursue potential biotech targets for highly-expected ROI. However, issues including any sources available for potential pipelines screening, how to commercialize your portfolio in China etc pose great challenges to the investors. What's more, how to exit and leave with money in pocket? Is China's upcoming second board stock market a good option?
China BioPharma Congress 2009, the grand finale of China's biopharma industry annually, is designed to gather together 400 executive-level professionals from China and overseas, bring conclusive views on 2009 biopharma industry and foresights on 2010.